Cabozantinib, a multi-target receptor tyrosine kinase inhibitor, decreases tumor growth and angiogenesis in a patient-derived dedifferentiated liposarcoma xenograft

Abstract

An abstract is not available for this record. Please visit the publisher website for more details.

Comparison Shortlist
0 journals
Est. APC Budget: $0
Compare Now